A citation-based method for searching scientific literature

Michele Ceribelli, Priscilla N Kelly, Arthur L Shaffer, George W Wright, Wenming Xiao, Yibin Yang, Lesley A Mathews Griner, Rajarshi Guha, Paul Shinn, Jonathan M Keller, Dongbo Liu, Paresma R Patel, Marc Ferrer, Shivangi Joshi, Sujata Nerle, Peter Sandy, Emmanuel Normant, Craig J Thomas, Louis M Staudt. Proc Natl Acad Sci U S A 2014
Times Cited: 127

List of co-cited articles
834 articles co-cited >1

Times Cited
  Times     Co-cited

Selective inhibition of BET bromodomains.
Panagis Filippakopoulos, Jun Qi, Sarah Picaud, Yao Shen, William B Smith, Oleg Fedorov, Elizabeth M Morse, Tracey Keates, Tyler T Hickman, Ildiko Felletar,[...]. Nature 2010

BET bromodomain inhibition as a therapeutic strategy to target c-Myc.
Jake E Delmore, Ghayas C Issa, Madeleine E Lemieux, Peter B Rahl, Junwei Shi, Hannah M Jacobs, Efstathios Kastritis, Timothy Gilpatrick, Ronald M Paranal, Jun Qi,[...]. Cell 2011

Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma.
Bjoern Chapuy, Michael R McKeown, Charles Y Lin, Stefano Monti, Margaretha G M Roemer, Jun Qi, Peter B Rahl, Heather H Sun, Kelly T Yeda, John G Doench,[...]. Cancer Cell 2013

Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study.
Sandy Amorim, Anastasios Stathis, Mary Gleeson, Sunil Iyengar, Valeria Magarotto, Xavier Leleu, Franck Morschhauser, Lionel Karlin, Florence Broussais, Keyvan Rezai,[...]. Lancet Haematol 2016

Targeting MYC dependence in cancer by inhibiting BET bromodomains.
Jennifer A Mertz, Andrew R Conery, Barbara M Bryant, Peter Sandy, Srividya Balasubramanian, Deanna A Mele, Louise Bergeron, Robert J Sims. Proc Natl Acad Sci U S A 2011

The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs.
Michela Boi, Eugenio Gaudio, Paola Bonetti, Ivo Kwee, Elena Bernasconi, Chiara Tarantelli, Andrea Rinaldi, Monica Testoni, Luciano Cascione, Maurilio Ponzoni,[...]. Clin Cancer Res 2015

RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia.
Johannes Zuber, Junwei Shi, Eric Wang, Amy R Rappaport, Harald Herrmann, Edward A Sison, Daniel Magoon, Jun Qi, Katharina Blatt, Mark Wunderlich,[...]. Nature 2011

Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia.
Mark A Dawson, Rab K Prinjha, Antje Dittmann, George Giotopoulos, Marcus Bantscheff, Wai-In Chan, Samuel C Robson, Chun-wa Chung, Carsten Hopf, Mikhail M Savitski,[...]. Nature 2011

Selective inhibition of tumor oncogenes by disruption of super-enhancers.
Jakob Lovén, Heather A Hoke, Charles Y Lin, Ashley Lau, David A Orlando, Christopher R Vakoc, James E Bradner, Tong Ihn Lee, Richard A Young. Cell 2013

Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study.
Céline Berthon, Emmanuel Raffoux, Xavier Thomas, Norbert Vey, Carlos Gomez-Roca, Karen Yee, David Christopher Taussig, Keyvan Rezai, Christophe Roumier, Patrice Herait,[...]. Lancet Haematol 2016

Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinib.
Baohua Sun, Bhavin Shah, Warren Fiskus, Jun Qi, Kimal Rajapakshe, Cristian Coarfa, Li Li, Santhana G T Devaraj, Sunil Sharma, Liang Zhang,[...]. Blood 2015

Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling.
A A Alizadeh, M B Eisen, R E Davis, C Ma, I S Lossos, A Rosenwald, J C Boldrick, H Sabet, T Tran, X Yu,[...]. Nature 2000

BET inhibitor resistance emerges from leukaemia stem cells.
Chun Yew Fong, Omer Gilan, Enid Y N Lam, Alan F Rubin, Sarah Ftouni, Dean Tyler, Kym Stanley, Devbarna Sinha, Paul Yeh, Jessica Morison,[...]. Nature 2015

Transcriptional plasticity promotes primary and acquired resistance to BET inhibition.
Philipp Rathert, Mareike Roth, Tobias Neumann, Felix Muerdter, Jae-Seok Roe, Matthias Muhar, Sumit Deswal, Sabine Cerny-Reiterer, Barbara Peter, Julian Jude,[...]. Nature 2015

Super-enhancers in the control of cell identity and disease.
Denes Hnisz, Brian J Abraham, Tong Ihn Lee, Ashley Lau, Violaine Saint-André, Alla A Sigova, Heather A Hoke, Richard A Young. Cell 2013

Suppression of inflammation by a synthetic histone mimic.
Edwige Nicodeme, Kate L Jeffrey, Uwe Schaefer, Soren Beinke, Scott Dewell, Chun-Wa Chung, Rohit Chandwani, Ivan Marazzi, Paul Wilson, Hervé Coste,[...]. Nature 2010

Brd4 coactivates transcriptional activation of NF-kappaB via specific binding to acetylated RelA.
Bo Huang, Xiao-Dong Yang, Ming-Ming Zhou, Keiko Ozato, Lin-Feng Chen. Mol Cell Biol 2009

The bromodomain protein Brd4 is a positive regulatory component of P-TEFb and stimulates RNA polymerase II-dependent transcription.
Moon Kyoo Jang, Kazuki Mochizuki, Meisheng Zhou, Ho-Sang Jeong, John N Brady, Keiko Ozato. Mol Cell 2005

Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma.
R Eric Davis, Vu N Ngo, Georg Lenz, Pavel Tolar, Ryan M Young, Paul B Romesser, Holger Kohlhammer, Laurence Lamy, Hong Zhao, Yandan Yang,[...]. Nature 2010

High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells.
Lesley A Mathews Griner, Rajarshi Guha, Paul Shinn, Ryan M Young, Jonathan M Keller, Dongbo Liu, Ian S Goldlust, Adam Yasgar, Crystal McKnight, Matthew B Boxer,[...]. Proc Natl Acad Sci U S A 2014

Oncogenically active MYD88 mutations in human lymphoma.
Vu N Ngo, Ryan M Young, Roland Schmitz, Sameer Jhavar, Wenming Xiao, Kian-Huat Lim, Holger Kohlhammer, Weihong Xu, Yandan Yang, Hong Zhao,[...]. Nature 2011

BET inhibitor OTX015 targets BRD2 and BRD4 and decreases c-MYC in acute leukemia cells.
Marie-Magdelaine Coudé, Thorsten Braun, Jeannig Berrou, Mélanie Dupont, Sibyl Bertrand, Aline Masse, Emmanuel Raffoux, Raphaël Itzykson, Marc Delord, Maria E Riveiro,[...]. Oncotarget 2015

Synergistic antitumor activity of lenalidomide with the BET bromodomain inhibitor CPI203 in bortezomib-resistant mantle cell lymphoma.
A Moros, V Rodríguez, I Saborit-Villarroya, A Montraveta, P Balsas, P Sandy, A Martínez, A Wiestner, E Normant, E Campo,[...]. Leukemia 2014

Histone recognition and large-scale structural analysis of the human bromodomain family.
Panagis Filippakopoulos, Sarah Picaud, Maria Mangos, Tracy Keates, Jean-Philippe Lambert, Dalia Barsyte-Lovejoy, Ildiko Felletar, Rudolf Volkmer, Susanne Müller, Tony Pawson,[...]. Cell 2012

Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer.
Shaokun Shu, Charles Y Lin, Housheng Hansen He, Robert M Witwicki, Doris P Tabassum, Justin M Roberts, Michalina Janiszewska, Sung Jin Huh, Yi Liang, Jeremy Ryan,[...]. Nature 2016

Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma.
Wyndham H Wilson, Ryan M Young, Roland Schmitz, Yandan Yang, Stefania Pittaluga, George Wright, Chih-Jian Lih, P Mickey Williams, Arthur L Shaffer, John Gerecitano,[...]. Nat Med 2015

Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma.
Yibin Yang, Arthur L Shaffer, N C Tolga Emre, Michele Ceribelli, Meili Zhang, George Wright, Wenming Xiao, John Powell, John Platig, Holger Kohlhammer,[...]. Cancer Cell 2012

Targeting bromodomains: epigenetic readers of lysine acetylation.
Panagis Filippakopoulos, Stefan Knapp. Nat Rev Drug Discov 2014

Inhibition of bromodomain proteins for the treatment of human diffuse large B-cell lymphoma.
Sally E Trabucco, Rachel M Gerstein, Andrew M Evens, James E Bradner, Leonard D Shultz, Dale L Greiner, Hong Zhang. Clin Cancer Res 2015

Targeting MYCN in neuroblastoma by BET bromodomain inhibition.
Alexandre Puissant, Stacey M Frumm, Gabriela Alexe, Christopher F Bassil, Jun Qi, Yvan H Chanthery, Erin A Nekritz, Rhamy Zeid, William Clay Gustafson, Patricia Greninger,[...]. Cancer Discov 2013

Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways.
Georg Lenz, George W Wright, N C Tolga Emre, Holger Kohlhammer, Sandeep S Dave, R Eric Davis, Shannon Carty, Lloyd T Lam, A L Shaffer, Wenming Xiao,[...]. Proc Natl Acad Sci U S A 2008

Recruitment of P-TEFb for stimulation of transcriptional elongation by the bromodomain protein Brd4.
Zhiyuan Yang, Jasper H N Yik, Ruichuan Chen, Nanhai He, Moon Kyoo Jang, Keiko Ozato, Qiang Zhou. Mol Cell 2005

BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia.
Christopher J Ott, Nadja Kopp, Liat Bird, Ronald M Paranal, Jun Qi, Teresa Bowman, Scott J Rodig, Andrew L Kung, James E Bradner, David M Weinstock. Blood 2012

BET domain co-regulators in obesity, inflammation and cancer.
Anna C Belkina, Gerald V Denis. Nat Rev Cancer 2012

Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes.
Bjoern Chapuy, Chip Stewart, Andrew J Dunford, Jaegil Kim, Atanas Kamburov, Robert A Redd, Mike S Lawrence, Margaretha G M Roemer, Amy J Li, Marita Ziepert,[...]. Nat Med 2018

Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4.
Jing Lu, Yimin Qian, Martha Altieri, Hanqing Dong, Jing Wang, Kanak Raina, John Hines, James D Winkler, Andrew P Crew, Kevin Coleman,[...]. Chem Biol 2015

BET and HDAC inhibitors induce similar genes and biological effects and synergize to kill in Myc-induced murine lymphoma.
Joydeep Bhadury, Lisa M Nilsson, Somsundar Veppil Muralidharan, Lydia C Green, Zhoulei Li, Emily M Gesner, Henrik C Hansen, Ulrich B Keller, Kevin G McLure, Jonas A Nilsson. Proc Natl Acad Sci U S A 2014

Kinase and BET Inhibitors Together Clamp Inhibition of PI3K Signaling and Overcome Resistance to Therapy.
Elias E Stratikopoulos, Meaghan Dendy, Matthias Szabolcs, Alan J Khaykin, Celine Lefebvre, Ming-Ming Zhou, Ramon Parsons. Cancer Cell 2015

Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer.
Irfan A Asangani, Vijaya L Dommeti, Xiaoju Wang, Rohit Malik, Marcin Cieslik, Rendong Yang, June Escara-Wilke, Kari Wilder-Romans, Sudheer Dhanireddy, Carl Engelke,[...]. Nature 2014

Master transcription factors and mediator establish super-enhancers at key cell identity genes.
Warren A Whyte, David A Orlando, Denes Hnisz, Brian J Abraham, Charles Y Lin, Michael H Kagey, Peter B Rahl, Tong Ihn Lee, Richard A Young. Cell 2013

Small molecule inhibitor screen identifies synergistic activity of the bromodomain inhibitor CPI203 and bortezomib in drug resistant myeloma.
Matthew B Siegel, Selina Qiuying Liu, Monika A Davare, Stephen E Spurgeon, Marc M Loriaux, Brian J Druker, Emma C Scott, Jeffrey W Tyner. Oncotarget 2015

BET protein antagonist JQ1 is synergistically lethal with FLT3 tyrosine kinase inhibitor (TKI) and overcomes resistance to FLT3-TKI in AML cells expressing FLT-ITD.
Warren Fiskus, Sunil Sharma, Jun Qi, Bhavin Shah, Santhana G T Devaraj, Christopher Leveque, Bryce P Portier, Swaminathan Iyer, James E Bradner, Kapil N Bhalla. Mol Cancer Ther 2014

Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins.
William W Lockwood, Kreshnik Zejnullahu, James E Bradner, Harold Varmus. Proc Natl Acad Sci U S A 2012

Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics.
Roland Schmitz, Ryan M Young, Michele Ceribelli, Sameer Jhavar, Wenming Xiao, Meili Zhang, George Wright, Arthur L Shaffer, Daniel J Hodson, Eric Buras,[...]. Nature 2012

BET protein proteolysis targeting chimera (PROTAC) exerts potent lethal activity against mantle cell lymphoma cells.
B Sun, W Fiskus, Y Qian, K Rajapakshe, K Raina, K G Coleman, A P Crew, A Shen, D T Saenz, C P Mill,[...]. Leukemia 2018

BET bromodomains mediate transcriptional pause release in heart failure.
Priti Anand, Jonathan D Brown, Charles Y Lin, Jun Qi, Rongli Zhang, Pedro Calderon Artero, M Amer Alaiti, Jace Bullard, Kareem Alazem, Kenneth B Margulies,[...]. Cell 2013

Inactivating mutations of acetyltransferase genes in B-cell lymphoma.
Laura Pasqualucci, David Dominguez-Sola, Annalisa Chiarenza, Giulia Fabbri, Adina Grunn, Vladimir Trifonov, Lawryn H Kasper, Stephanie Lerach, Hongyan Tang, Jing Ma,[...]. Nature 2011

DRUG DEVELOPMENT. Phthalimide conjugation as a strategy for in vivo target protein degradation.
Georg E Winter, Dennis L Buckley, Joshiawa Paulk, Justin M Roberts, Amanda Souza, Sirano Dhe-Paganon, James E Bradner. Science 2015

Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.